{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282679530964992.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.11251/ojjscn1969.8.455"}},{"identifier":{"@type":"NAID","@value":"130004184250"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/1977062492"}}],"dc:title":[{"@language":"en","@value":"Preliminary Observations of Plasma Carbamazepine Concentration in Epileptic Children"},{"@value":"抗てんかん薬Carbamazepine (Tegretol) の血中濃度に関する研究 (予報)"}],"dcterms:alternative":[{"@value":"血中濃度/投与量の相関について"}],"description":[{"type":"abstract","notation":[{"@language":"en","@value":"A preliminary study on the plasma concentration of carbamazepine (Tegretol) in children was performed as related with the oral dosage.<BR>Forty children at the pediatric seizure clinic of a university hospital (group A, aged 1-14, mean 8years) and 26 institutionalized both mentally and physically severely handicapped epileptic patients (group B, aged 5-23, mean 13 years) were selectedfor the study.<BR>Plasma levels of carbamazepine, phenobarbital, etc. were determined by the modification of Kupferberg's. GLC methods.<BR>In both groups A and B plasma carbamazepine Concentrations inμg/ml, plotted against dosage in mg/kg/day, showed great individual variation.<BR>However, there was a definite tendency that the patients taking carbamazepine, but not phenobarbital or primidone, showed high plasma level/dosage ratio ofcarbamazepine; while the carbamazepine plasma level, or plasma level/dosage ratio, was low in those on both carbamazepine and barbiturates, especially in those with high phenobarbital concentration above potentially toxic level.<BR>These probable drug interaction may have resulted in the differences of calculated values in both groups shown below.<BR>In group A, plasma levels (3.58±2.43μg/m<I>l</I>) to dosage (12.5±3.27mg/kg/day) ratios of carbamazepine were 0.28±0.18; and group B presented 1.83±1.38μg/m<I>l</I>, 13.10±7.19 mg/kg/day and 0.15±0.11, respectively."},{"@value":"抗てんかん薬Carbamazepine (Tegretol, 以下CARBと略す) を持続投与中の小児を対象に, その血中濃度を測定し, 投与量との相関を求めた.<BR>血中濃度測定方法はKupferberg (1972年) の方法に準じ, 通常被検血漿1mlを水酸化ナトリウムを加えてアルカリ性とし, Chloroformで抽出, 濃縮後, 反応触媒にTrimethylchlorosilaneを使用して, N, O-bis-trimethylsilyl acetamideでtrimethylsilyl化し, 4-Benzyldiphenylを内部標準物質として, 3%OV-17カラムを用い, gas-liquid chromatographyにより定量分析を行なったが, その回収率は100.03±2.53%とすぐれていた.<BR>対象は, (A) 一般大学病院外来患児40名ならびに (B) 一重症心身障害児施設収容児 (者) 26名で, それぞれの血中濃度/投与量・比は個体差が大であり, 血中濃度と投与量との間に一定の相関を見出し得なかったが, A, B両群をまとめて比較すると, A群は年齢1～14才 (平均8才), 体重11～43kg (平均26.5kg), CARB1日投与量100～600mg (平均320mg), B群は年齢5～23才 (平均13才), 体重14～49kg (平均27.8kg), CARB1日投与量100～700mg (平均330mg) で, たまたま両群の平均体重, CARB1日投与量は等しかったが, A群は血中濃度3.58±2.43μ9/ml, 投与量12.51±3.27mg/kg/day, 血中濃度 (μg/ml) /投与量 (mg/kg/day) ・比0.28±0.18, B群はそれぞれ1.83±1.38μg/ml, 13.10±7.19mg/kg/day, 比率0.15±0.11で, その血中濃度, 血中濃度/投与量・比は0.5%以下の危険率でB群が低値であった.<BR>また, この両群の差異に関し個々に検討すると, A群の半数近くを占めるPhenobarbita1, Primidone等を併用しない者はCARBの血中濃度/投与量・比が大であり, B群に多いPB血中濃度がpotentially toxic level以上にある者はこの比が小なる傾向が明らかであった.<BR>CARBの吸収, 代謝, 排泄, 他薬剤との相互作用, 有効血中濃度に関してはいまだ不明な点が多いが, これらを解明していく上で, また臨床の実際において, その血中濃度測定の意義を強調したい."}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1030285133300621188","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"60050465"},{"@type":"NRID","@value":"1000060050465"},{"@type":"NRID","@value":"9000255728667"},{"@type":"NRID","@value":"9000256114639"},{"@type":"NRID","@value":"9000007756390"},{"@type":"NRID","@value":"9000020395472"},{"@type":"NRID","@value":"9000256114354"},{"@type":"NRID","@value":"9000004140690"},{"@type":"NRID","@value":"9000020466163"},{"@type":"NRID","@value":"9000020382366"},{"@type":"NRID","@value":"9000256113110"},{"@type":"NRID","@value":"9000006090995"}],"foaf:name":[{"@language":"en","@value":"MIURA Hisao"},{"@language":"ja","@value":"三浦 寿男"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Pediatrics, School of Medicine, Kitasato University"},{"@language":"ja","@value":"北里大学医学部小児科"}]},{"@id":"https://cir.nii.ac.jp/crid/1410009221986024195","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000256121799"}],"foaf:name":[{"@language":"en","@value":"MINAGAWA Kimio"},{"@language":"ja","@value":"皆川 公夫"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Pediatrics, School of Medicine, Kitasato University"},{"@language":"ja","@value":"北里大学医学部小児科"}]},{"@id":"https://cir.nii.ac.jp/crid/1410009221986024193","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000256121800"}],"foaf:name":[{"@language":"en","@value":"YAGI Jiro"},{"@language":"ja","@value":"八木 二郎"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Shimada Hospital Home for Both Mentally and Physically Severely Handicapped Children"},{"@language":"ja","@value":"島田療育園"}]},{"@id":"https://cir.nii.ac.jp/crid/1410009221986024196","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000256121801"}],"foaf:name":[{"@language":"en","@value":"KATO Yuzuru"},{"@language":"ja","@value":"加藤 譲"}],"jpcoar:affiliationName":[{"@language":"ja","@value":"北里バイオケミカル・ラボラトリーズ"},{"@language":"en","@value":"Kitasato Biochemical Laboratories"}]},{"@id":"https://cir.nii.ac.jp/crid/1410009221986024192","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000256121802"}],"foaf:name":[{"@language":"en","@value":"KANEKO Tsugio"},{"@language":"ja","@value":"金子 次雄"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Kitasato Biochemical Laboratories"},{"@language":"ja","@value":"北里バイオケミカル・ラボラトリーズ"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00290831"},{"@type":"EISSN","@value":"18847668"}],"prism:publicationName":[{"@language":"en","@value":"NO TO HATATSU"},{"@language":"ja","@value":"脳と発達"},{"@language":"en","@value":"NO TO HATATSU"},{"@language":"ja","@value":"脳と発達"}],"dc:publisher":[{"@language":"en","@value":"THE JAPANESE SOCIETY OF CHILD NEUROLOGY"}],"prism:publicationDate":"1976","prism:volume":"8","prism:number":"6","prism:startingPage":"455","prism:endingPage":"462"},"url":[{"@id":"https://search.jamas.or.jp/link/ui/1977062492"}],"availableAt":"1976","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Carbamazepine","dc:title":"Carbamazepine"},{"@id":"https://cir.nii.ac.jp/all?q=%E6%8A%97%E3%81%A6%E3%82%93%E3%81%8B%E3%82%93%E8%96%AC%E8%A1%80%E4%B8%AD%E6%BF%83%E5%BA%A6","dc:title":"抗てんかん薬血中濃度"},{"@id":"https://cir.nii.ac.jp/all?q=%E8%96%AC%E7%89%A9%E9%96%93%E7%9B%B8%E4%BA%92%E4%BD%9C%E7%94%A8","dc:title":"薬物間相互作用"},{"@id":"https://cir.nii.ac.jp/all?q=%E3%81%A6%E3%82%93%E3%81%8B%E3%82%93","dc:title":"てんかん"}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:0037804386"},{"@type":"CIA","@value":"130004184250"}]}